Форма документа : Стаття із журналу Шифр видання : Автор(и) : Gordienko I. Назва : Cell signalling in cancer biology and management Місце публікування : Онкологія. - Київ, 2021. - Т. 23, № 4. - С. 232 (Шифр ОУ3/2021/23/4) MeSH-головна: КЛЕТОЧНАЯ МЕХАНОТРАНСДУКЦИЯ -- MECHANOTRANSDUCTION, CELLULAR БИОХИМИЧЕСКИЕ ПРОЦЕССЫ -- BIOCHEMICAL PROCESSES НОВООБРАЗОВАНИЯ -- NEOPLASMS Анотація: A signal transduction pathway is a series of steps by which a signal on a cell’s surface is converted into a specific cellular response. Signal transduction, which occurs in each cell of the body, is largely required for the correct functioning of the whole organism. Regulation of cell cycle and proliferation, migration, differentiation, viability versus cell death, metabolism is not all processes that are coordinated by signal transduction pathways. That is why it is not surprising that deregulation in cell signaling may have a considerable impact on the homeostasis of the cell. This lecture will be discussed three main signaling pathways: JAK/STAT, Ras/MEK/Erk, and PI3K/Akt/mTOR by the reason, they are very frequently activated in all types of cancer and are common effectors of different upstream lesions. It will be discussed how to use knowledge about signal transduction pathways in normal and cancer cells for the development of target therapy. On the example of one signal molecule, cell surface receptor SLAMF1 or CD150 will be showed complexity, diversity, and multifunctionality of cell signaling and its potential in improving diagnosis, prognosis, and therapy prediction of cancer. The differential expression among various types of hematological malignancies allows considering CD150 as a diagnostical and potential prognostic marker. Moreover, CD150 may be a target for antibody-based or measles virus oncolytic therapy. Due to CD150 signaling properties, it is involved in the regulation of malignant cell fate decision and tumor microenvironment in Hodgkin’s lymphoma and chronic lymphocytic leukemia |